BSPII Activators
BSPII, also known as Brain-Specific Serine Protease Inhibitor II, is a protein primarily expressed in the brain and belongs to the family of serine protease inhibitors. Its function is to regulate the activity of serine proteases, which are enzymes involved in various physiological processes such as blood clotting, inflammation, and digestion. Specifically, BSPII acts as an inhibitor of serine proteases, exerting control over their activity to prevent excessive proteolysis and maintain homeostasis in the brain microenvironment. By inhibiting serine proteases, BSPII plays a crucial role in protecting neuronal cells from damage and maintaining their structural and functional integrity.
Activation of BSPII involves intricate molecular mechanisms that regulate its expression and function. One of the key regulatory mechanisms is post-translational modification, including phosphorylation and glycosylation, which can modulate BSPII activity and stability. Additionally, transcriptional regulation mediated by various transcription factors and signaling pathways contributes to the activation of BSPII. For instance, signaling cascades such as the MAPK/ERK pathway and the PI3K/AKT pathway have been implicated in the regulation of BSPII expression. Furthermore, environmental cues and cellular stressors can also influence BSPII activation, highlighting its dynamic responsiveness to physiological and pathological conditions in the brain. Overall, elucidating the mechanisms underlying BSPII activation is essential for understanding its role in brain function and its implications in neurological disorders.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bradykinin | 58-82-2 | sc-507311 | 5 mg | $110.00 | ||
Bradykinin is an endogenous peptide that may potentially activate BSPII. It acts through G protein-coupled receptors, leading to the activation of various intracellular signaling pathways, including calcium release. The specific mechanism through which bradykinin influences BSPII requires further investigation, but this endogenous peptide offers a potential avenue for exploring direct or indirect activation by targeting G protein-coupled receptor-mediated signaling pathways. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $57.00 $159.00 $275.00 $678.00 | 37 | |
Prostaglandin E2 (PGE2) is a lipid mediator that may potentially activate BSPII. It acts through G protein-coupled receptors, influencing intracellular signaling pathways. PGE2 can modulate cyclic AMP (cAMP) levels, and its downstream effects could impact BSPII function. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin is an adenylate cyclase activator that may potentially activate BSPII. Adenylate cyclase catalyzes the formation of cyclic AMP (cAMP), a second messenger involved in various cellular processes, including signal transduction. Modulation of cAMP levels by forskolin could impact protein kinase A (PKA) activity, and downstream effects could influence BSPII function. | ||||||
ATP | 56-65-5 | sc-507511 | 5 g | $17.00 | ||
ATP is an endogenous nucleotide that may potentially activate BSPII. ATP acts on purinergic receptors, leading to intracellular calcium release. The specific mechanism through which ATP influences BSPII requires further investigation, but this endogenous nucleotide offers a potential avenue for exploring direct or indirect activation by targeting purinergic signaling pathways. | ||||||
Dibutyryl-cGMP | 51116-00-8 | sc-200321 sc-200321A | 10 mg 50 mg | $153.00 $398.00 | 11 | |
Dibutyryl cGMP is a cyclic GMP (cGMP) analog that may potentially activate BSPII. cGMP is a second messenger involved in various cellular processes, including signal transduction. Modulation of cGMP levels can impact protein kinase G (PKG) activity, and downstream effects could influence BSPII function. | ||||||
Angiotensin II, Human | 4474-91-3 | sc-363643 sc-363643A sc-363643B sc-363643C | 1 mg 5 mg 25 mg 100 mg | $51.00 $100.00 $310.00 $690.00 | 3 | |
Angiotensin II is a peptide hormone that may potentially activate BSPII. It acts through angiotensin receptors, leading to intracellular signaling events. The specific mechanism through which angiotensin II influences BSPII requires further investigation, but this endogenous peptide hormone offers a potential avenue for exploring direct or indirect activation by targeting angiotensin receptor-mediated signaling pathways. | ||||||
(±)-Bay K 8644 | 71145-03-4 | sc-203324 sc-203324A sc-203324B | 1 mg 5 mg 50 mg | $84.00 $196.00 $817.00 | ||
Bay K 8644 is an L-type calcium channel agonist that may potentially activate BSPII. L-type calcium channels play a role in calcium influx, and their activation can lead to intracellular calcium release. The specific mechanism through which Bay K 8644 influences BSPII requires further investigation, but this chemical provides a potential avenue for exploring direct or indirect activation by targeting calcium channel-mediated signaling pathways. | ||||||
Substance P | 33507-63-0 | sc-201169 | 1 mg | $56.00 | ||
Substance P is an endogenous neuropeptide that may potentially activate BSPII. It acts through neurokinin receptors, leading to intracellular signaling events. The specific mechanism through which substance P influences BSPII requires further investigation, but this endogenous neuropeptide offers a potential avenue for exploring direct or indirect activation by targeting neurokinin receptor-mediated signaling pathways. | ||||||